Bausch + Lomb Corporation - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BLCO New York 2830 www.bausch.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Bausch + Lomb Corporation

BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser - Sep 14th, 2026 9:14 am
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser - Sep 11th, 2026 4:11 am
1 Cash-Producing Stock with Exciting Potential and 2 We Ignore - Sep 9th, 2026 7:30 am
Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience - Sep 2nd, 2026 5:00 am
Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds - Sep 1st, 2026 4:58 am
Bausch + Lomb (BLCO) Stock Trades Below Fair Value As Caution Lingers - Aug 29th, 2026 5:06 pm
1 Unpopular Stock That Deserves a Second Chance and 2 We Turn Down - Aug 28th, 2026 5:12 am
3 Healthcare Stocks We Steer Clear Of - Aug 27th, 2026 8:33 am
Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial - Aug 26th, 2026 4:11 am
A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q2 Earnings: Bausch + Lomb (NYSE:BLCO) Vs The Rest Of The Pack - Aug 25th, 2026 10:54 am
Bausch + Lomb Advances Two First-in-Class Eye Health Therapies - Aug 25th, 2026 9:53 am
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal - Aug 24th, 2026 7:01 pm
Bausch + Lomb Plans to Advance Dual-Action Eye Drop Targeting Evaporative and Inflammatory Dry Eye Disease to Phase 3 - Aug 24th, 2026 3:38 pm
Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results - Aug 24th, 2026 2:30 pm
COO Stock Surges 22% in Past Three Months: What's Driving the Uptrend? - Aug 18th, 2026 10:39 am
3 Stocks Under $50 We’re Skeptical Of - Aug 18th, 2026 6:45 am
Brixton Biosciences Strengthens Board with Industry Veterans as Company Advances Towards Commercialization of Reneurx™ Nerve-Selective Therapy for Pain Associated with Knee Osteoarthritis - Aug 18th, 2026 5:30 am
Insider Sheds Nearly 53,000 Shares of Consumer Health Stock, Valued at Almost $900,000 - Aug 13th, 2026 7:00 am